Home
overview

SMi is proud to present its 4th annual Allergies conference which returns to London in July 2017 to reflect on the ongoing issues and latest developments in this field.


This year's event will bring together industry leaders to discuss the latest challenges and changes in the fields of allergen immunotherapy. We will explore novel approaches to treatment, exploring biomarkers and targeted treatments. We will identify challenges to device development and drug delivery, deepen our understanding of the problems relating to these diseases, and discuss the topic of standardisation.


As the prevalence of allergic diseases has increased so has diagnostic technology. Additionally, cutting edge developments in targeted drugs and preventative measures are currently revolutionising the ways in which pharmaceutical and biotech companies are addressing allergies.


Presentations and selected case studies from industry experts on paediatric allergies and immunotherapy, novel approaches to treatment, key decision makers in these fields and unique networking opportunities will make this an event a not to miss opportunity

 

  • Highlight the latest innovative strategies to tackling allergies ranging from food to pollution
  • Understand and address the regulatory challenges facing inhalation device development for asthma
  • Gain insight into molecular diagnostic and biomarkers for allergic disease
  • Discuss challenges and potential solutions to in patient recruitment and phenology
  • Develop deeper understanding of the ongoing problems still facing chronic allergy sufferers

 

Chief, Vice Presidents, Heads, Senior Directors, Directors, Principals, Principal Scientists, Team/ Project Leaders, Clinicians, Medical Officers of:

  • Immunotherapy Drug Discovery
  • Allergy Medicine/ Therapeutics
  • Allergy Pharmacology
  • Immunotherapy
  • Research Immunology
  • Pharmacology
  • Allergy Devices
  • Medical Devices
  • Immunotherapy
  • Inflammation and Autoimmunity
  • Immunology
  • Allergy Cell Biology
  • Allergy Medicine Regulation

from pharmaceutical companies, biotech companies, hospitals and academic institutions.

 

ALK-Abello A/S; Allergopharma GmbH & Co. KG; Allergy Therapeutics Ltd; anaphylaxis campagne; Anergis; Biomay AG; Chiesi Pharmaceuticals S.p.A.; Danone Research Centre for Specialised Nutrition; DBV Technologies; GenOway; Glenmark Pharmaceuticals Europe; HAL Allergy; Imperial; Imperial College London Faculty of Medicine; Indoor Biotechnologies, Inc.; Inflamax Research, Inc.; Kings College London; Laboratorios Leti; Medi Club Georgia; MedImmune; Microsample Ltd; Nestle Research Center; NIBSC; Nippon Medical School; Stallergenes; Stallergenes Greer Plc; The London Allergy and Immunology Centre; Ucl Hospitals; VIAJES EL CORTE INGLES SA;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Jean Cuine

Jean Cuine, Global Head of Non-clinical & Pharmaceutical Development, Stallergenes

9:10 Product Standardisation: Current status & key challenges

Jean Cuine

Jean Cuine, Global Head of Non-clinical & Pharmaceutical Development, Stallergenes

  • The need for allergen product standardisation and characterisation standardisation
  • The challenge of different regulatory requirements for product standardization
  • The challenge of relevant allergen quantification in product standardisation
     
  • 9:50 Introduction to the world of ‘allergology’ and its impact on industry

    10:30 Morning Coffee

    11:00 State-of-the art characterisation and control of complex allergen preparations for immunotherapy

    Rob Van Den Hout

    Rob Van Den Hout, Principal Scientist , HAL Allergy

  • Regulatory demand for manufacturing and quality control
  • Case studies on the characterisation and standardisation of modified allergen extracts and final products
  • Analytical tools for assessing stability of aluminum hydroxide adsorbed allergen preparations
     
  • 11:40 Applications and mechanisms of immunotherapy in allergic rhinitis and asthma

    Mohamed  Shamji

    Mohamed Shamji, Group leader/Senior Research Fellow, Imperial College London Faculty of Medicine

  • Clinical and immunologic tolerance as hallmarks of successful allergen immunotherapy (AIT)
  • Effect of AIT on innate effector cells.
  • The associated induction of distinct phenotypes of regulatory T and B cells during treatment with allergen immunotherapy
  • The identification of novel biomarkers with potential to predict the clinical response to AIT
  • Immune mechanisms of novel therapeutic strategies for more effective and safer AIT.

     

  • 12:20 Networking Lunch

    13:30 Recombinant B-cell epitope derived fusion proteins for efficient short course allergy immunotherapy

    Rainer  Henning

    Rainer Henning, CEO, Biomay AG

  • The pros and cons of extract based immunotherapy (SCIT and SLIT)
  • Design principles of B-cell epitope derived fusion proteins (PCFiT technology)
  • Immunological properties of PCFiT vaccines
  • Results of clinical evaluation of grass pollen allergy vaccine BM32 based on PCFiT
  • 14:10 Speaking slot reserved for DBV

    Lucie Mondoulet

    Lucie Mondoulet, Deputy CSO, DBV Technologies

    14:50 Afternoon Tea

    15:20 Hypoallergenic immunotherapeutic drugs for the treatment of respiratory and food allergies

    Dirk-Jan Opstelten

    Dirk-Jan Opstelten, R&D Director, HAL Allergy

  • Introduction to existing and novel approaches to develop hypoallergenic immunotherapies
  • Routes of administration
  • Benefits of subcutaneous immunotherapy with modified allergens
  • Clinical data supporting the efficacy and safety of hypoallergenic immunotherapeutic drugs
     
  • 16:00 Depigmented allergoids for treating cat and Alternaria allergies

    Jeronimo  Carnes

    Jeronimo Carnes, R&D Director of Immunology & Allergy, Leti Laboratories

  • High quality “named patient products” for treating prevalent allergies
  • From raw material to allergen immunotherapy: Manufacturing process and allergen extract characterization according to the European Guidelines requirements
  • Safety designed immunotherapy- measurement of the interaction IgE-Allergen extract during the development process, as a guaranty of safety
  • Immunological efficacy as a prerequisite before human treatment: Blocking antibodies and stimulation of immunological mediators
     
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Jean Cuine

    Jean Cuine, Global Head of Non-clinical & Pharmaceutical Development, Stallergenes

    9:10 Treatment of grass and birch pollen allergies – comparison of extract based and recombinant strategies

    Andreas Nandy

    Andreas Nandy, Director External Innovation & Partner Management, Allergopharma (acquired by Merck Group)

  • Products currently on the market
  • Clinical experience with recombinants and extracts
  • The hypoallergenic concept
  • Future developments
     
  • 9:50 Allergens and regulation: The challenge!

    Hugo Braga Tavares

    Hugo Braga Tavares, Member of the Pediatric Committee, (EMA) representing INFARMED

  • The context of allergen studies
  • What is known? What still has to be demonstrated?
  • The Allergen Standard Paediatric investigation Plan (PIP)
  • What has happened since Standard Allergen PIP approval?
     
  • 10:30 Morning Coffee

    11:00 Dust mite allergy immunotherapy treatment: The journey so far and oral alternatives

    Tim Higenbottam

    Tim Higenbottam, Research & Development Director, Allergy Therapeutics Ltd

  • Understanding methods to defining the correct dosage when administering subcutaneous immunotherapies
  • The importance of pain-free alternatives for children: factors to consider when developing an oral allergy vaccines
  • The barriers still faced in encouraging clinician uptake of oral vaccines vs conventional injection therapy
     
  • 11:40 Nutritional approach for allergy prevention during the perinatal period

    Sophie Nutten

    Sophie Nutten, Group Leader of the Allergy group, Nestle Research Center

  • Does maternal nutrition (lipids, probiotics, fibres…) have an impact?
  • Is there an association between breast milk components and allergy risk in infants? Results from mother/infants cohorts
  • Latest results on complementary feeding: is there an intervention window for the introduction of allergens?
     
  • 12:20 Networking Lunch

    13:30 Purified allergens and immunoassays for molecular diagnostics, product standardisation and food safety

    Hayley Gallagher

    Hayley Gallagher, Product and Service Specialist, Indoor Biotechnologies, Inc.

  • Purified allergens for allergy research and molecular diagnostics
  • Molecular reference standards for allergen standardisation
  • Specific immunoassays for quantification of allergens
  • Development of multiplex assay for detection of allergens in food
     
  • 14:10 Using DNA vaccine based technology to prevent potentially life-threatening allergies

    Salim Mujais

    Salim Mujais, Senior Vice President, Astellas Pharma

  • Unique mechanism of action for Astellas’ development program for DNA vaccine based therapy
  • Lessons learned from conversations with regulatory agency(ies) regarding safety with a first-in-class product
  • Obtaining priority designation based on preclinical work, which is unique 
     
  • 14:50 Afternoon Tea

    15:20 Diagnostic tests in paediatric allergy

    Adnan Custovic

    Adnan Custovic, Clinical Professor of Paediatric Allergy, Imperial College London

    16:00 Application of biomarkers and patient characteristics to personalise the treatment of Asthma & COPD

    17:00 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Andreas Nandy

    Andreas Nandy

    Director External Innovation & Partner Management, Allergopharma (acquired by Merck Group)
    Dirk-Jan Opstelten

    Dirk-Jan Opstelten

    R&D Director, HAL Allergy
    Jean Cuine

    Jean Cuine

    Global Head of Non-clinical & Pharmaceutical Development, Stallergenes
    Jeronimo  Carnes

    Jeronimo Carnes

    R&D Director of Immunology & Allergy, Leti Laboratories
    Rob Van Den Hout

    Rob Van Den Hout

    Principal Scientist , HAL Allergy

    Adnan Custovic

    Clinical Professor of Paediatric Allergy, Imperial College London
    Adnan Custovic

    Amena Warner

    Head of Clinical Services, Allergy UK
    Amena Warner

    Andreas Nandy

    Director External Innovation & Partner Management, Allergopharma (acquired by Merck Group)
    Andreas Nandy

    Dirk-Jan Opstelten

    R&D Director, HAL Allergy
    Dirk-Jan Opstelten

    Hayley Gallagher

    Product and Service Specialist, Indoor Biotechnologies, Inc.
    Hayley Gallagher

    Hugo Braga Tavares

    Member of the Pediatric Committee, (EMA) representing INFARMED
    Hugo Braga Tavares

    Jean Cuine

    Global Head of Non-clinical & Pharmaceutical Development, Stallergenes
    Jean Cuine

    Jeronimo Carnes

    R&D Director of Immunology & Allergy, Leti Laboratories
    Jeronimo  Carnes

    Kate Rochlin

    Founder & CSO, Immunovent
    Kate Rochlin

    Lucie Mondoulet

    Deputy CSO, DBV Technologies
    Lucie Mondoulet

    Mohamed Shamji

    Group leader/Senior Research Fellow, Imperial College London Faculty of Medicine
    Mohamed  Shamji

    Rainer Henning

    CEO, Biomay AG
    Rainer  Henning

    Rob Van Den Hout

    Principal Scientist , HAL Allergy
    Rob Van Den Hout

    Salim Mujais

    Senior Vice President, Astellas Pharma
    Salim Mujais

    Sophie Nutten

    Group Leader of the Allergy group, Nestle Research Center
    Sophie Nutten

    Tim Higenbottam

    Research & Development Director, Allergy Therapeutics Ltd
    Tim Higenbottam

    Sponsors

    VENUE

    Holiday Inn Kensington Forum

    97 Cromwell Road , London, United Kingdom

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Sponsors


    DBV Technologies

    Sponsors
    http://www.dbv-technologies.com/en

    DBV Technologies is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin®. Our therapeutic approach is based on epicutaneous immunotherapy, or EPIT®, our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin®. We are advancing this unique technology to treat patients, including infants and children, suffering from severe food allergies (Peanut, Milk, Egg).


    Indoor Biotechnologies

    Sponsors
    http://www.inbio.com/

    Indoor Biotechnologies manufactures purified natural and recombinant allergens, ELISA and multiplex immunoassays for allergen detection, dust sampling devices, and a home consumer test for dust mite allergen detection. We provide contract research and analytical services for allergen, endotoxin and mould antigen testing at our laboratories at UK, USA and India.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.